US EditionStakeholder Considerations for MFP Effectuation in Part B
Summary by avalerehealth.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Stakeholder Considerations for MFP Effectuation in Part B
Background Under the Medicare Drug Price Negotiation Program, the Centers for Medicare & Medicaid Services (CMS) negotiates a maximum fair price (MFP) for a set number of drugs each year. To date, 10 Part D drugs have been negotiated for the Initial Price Applicability Year (IPAY) 2026 and 15 additional Part D drugs are currently being negotiated for IPAY 2027. Beginning in IPAY 2028, Part B drugs will also be eligible for selection. After CMS n…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
